300122:SZSEChongqing Zhifei Biological Products Co., Ltd. Class A Analysis

Chongqing Zhifei Biological Products is trading at CNY 16.28, well below its 20‑day SMA (CNY 16.59) and far beneath the 200‑day SMA (CNY 20.13), signaling a bearish technical backdrop. However, the MACD histogram turned positive and the signal line is bullish, while the RSI sits at 42, suggesting limited oversold pressure and a potential short‑term bounce toward the nearby resistance around CNY 17.65.
Fundamentally, the company is under pressure: revenue has slumped 40%, operating and profit margins are negative, and free cash flow is deeply in the red. Debt is high (debt‑to‑equity ≈ 48) and the balance sheet is strained, casting doubt on the sustainability of its 5.22% dividend despite a modest payout ratio. The DCF fair‑value estimate of CNY 1.19 is dramatically lower than the market price, implying a severe overvaluation, even though the forward PE of ~10.8 is well under the industry average of 26.3 and analysts target a median price of CNY 23.5, indicating perceived upside. The market sentiment is extremely greedy (Fear‑Greed Index 81.8), which may be inflating the stock beyond its intrinsic merits.